Evidence map›Paper›PMID 25376609›Full record

ArticleMolecular cancer therapeutics2015

ΔNP63α transcriptionally activates chemokine receptor 4 (CXCR4) expression to regulate breast cancer stem cell activity and chemotaxis.

Andrew J DeCastro, Pratima Cherukuri, Amanda Balboni, James DiRenzo

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. A novel and selective inhibitor of PKC ζ potently inhibits human breast cancer metastasis in vitro and in mice.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Andrew J DeCastroDepartment of Pharmacology and Toxicology, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. Program in Experimental and Molecular Medicine, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Pratima CherukuriDepartment of Pharmacology and Toxicology, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Amanda BalboniDepartment of Pharmacology and Toxicology, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. Program in Experimental and Molecular Medicine, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
James DiRenzoDepartment of Pharmacology and Toxicology, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. James.DiRenzo@Dartmouth.edu.
Dartmouth College · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
Role of DN-p63 in Preservation of Self RenewalR01CA108539 · NCI · DARTMOUTH COLLEGE · PI DIRENZO, JAMES · 2005 to 2009
$1.4M
NCI NIH HHS 5R01CA108539-05NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA108539
6 · The paper itself

Abstract

ΔNP63α, the predominant TP63 isoform expressed in diverse epithelial tissues, including the mammary gland, is required for the preservation of stem cells and has been implicated in tumorigenesis and metastasis. Despite data characterizing ΔNP63α as a master regulator of stem cell activity, identification of the targets underlying these effects is incompletely understood. Recently, ΔNP63α was identified as a key regulator in the promotion of proinflammatory programs in squamous cell carcinoma of the head and neck. Inflammation has been implicated as a potent driver of cancer stem cell phenotypes and metastasis. In this study, we sought to identify novel targets of ΔNP63α that confer cancer stem cell and prometastatic properties. Data presented here identify the gene encoding the chemokine receptor 4 (CXCR4) as a transcriptional target of ΔNP63α. Our data indicate that ΔNP63α enhances CXCR4 expression in breast cancer cells via its binding at two regions within the CXCR4 promoter. The CXCR4 antagonist AMD3100 was used to demonstrate that the pro-stem cell activity of ΔNP63α is mediated through its regulation of CXCR4. Importantly, we show that ΔNP63α promotes the chemotaxis of breast cancer cells towards the CXCR4 ligand SDF1α, a process implicated in the trafficking of breast cancer cells to sites of metastasis. This study highlights CXCR4 as a previously unidentified target of ΔNP63α, which plays a significant role in mediating ΔNP63α-dependent stem cell activity and chemotaxis toward SDF1α. Our findings suggest that ΔNP63α regulation of CXCR4 may have strong implications in the regulation of cancer stem cells and metastasis.

Indexed as

BenzylaminesBreast NeoplasmsCell Line, TumorChemotaxisCyclamsFemaleGene Expression Regulation, NeoplasticHeterocyclic CompoundsHumansMCF-7 CellsNeoplastic Stem CellsPromoter Regions, GeneticProtein IsoformsReceptors, CXCR4Transcription FactorsTumor Suppressor ProteinsBenzylaminesCXCR4 protein, humanCyclamsHeterocyclic CompoundsplerixaforProtein IsoformsReceptors, CXCR4TP63 protein, humanTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID25376609
PMCPMC4297234
OpenAlexW2097597706

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.